Press Releases Moberg Pharma AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 08:59:30 14/05/2024 pm IST			5-day change	1st Jan Change
28.04 ^SEK	+0.65%		-27.95%	+84.47%

07/05	Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
06/05	Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure	CI

Bulletin from Moberg Pharma's AGM on May 14[th], 2024	14/05	AQ
Moberg Pharma - Positive momentum	08/05	AQ
Moberg Pharma's interim report January - March 2024	07/05	AQ
National approval for MOB-015 in all 13 countries	06/05	AQ
Moberg Pharma : Launch update for MOB-015	23/04	PU
Moberg Pharma : Launch update for MOB-015	23/04	PU
Notice of Annual General Meeting in Moberg Pharma AB (publ)	12/04	AQ
Moberg Pharma Annual report for 2023	12/04	AQ
Moberg Pharma : Corporate Governance Report 2023	12/04	PU
Moberg Pharma : Application submitted to include an additional terbinafine supplier	08/04	PU
The Nomination Committee's proposal to the Annual General Meeting 2024	19/02	AQ
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication	07/02	AQ
Moberg Pharma's Interim report January - September 2023	07/11	AQ
Moberg Pharma strengthens the organization	07/11	AQ
Moberg Pharma's Nomination Committee appointed	17/23/17	AQ
MOBERG PHARMA HAS COMPLETED ENROLLMENT TO THE PHASE 3 STUDY FOR MOB-015 IN NORTH AMERICA	09/23/09	AQ
Bulletin from Moberg Pharma's Extraordinary General Meeting	09/23/09	AQ
Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America	06/23/06	AQ
New number of shares and votes in Moberg Pharma AB (publ)	29/23/29	AQ
Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)	13/23/13	AQ

No results for this search